PE20161443A1 - Compuestos - Google Patents
CompuestosInfo
- Publication number
- PE20161443A1 PE20161443A1 PE2016001250A PE2016001250A PE20161443A1 PE 20161443 A1 PE20161443 A1 PE 20161443A1 PE 2016001250 A PE2016001250 A PE 2016001250A PE 2016001250 A PE2016001250 A PE 2016001250A PE 20161443 A1 PE20161443 A1 PE 20161443A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- alcoxyl
- cycloalkyl
- disease
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE PIRAZOL DE FORMULA (I) DONDE R1 ES H, ALCOXILO C1-C3, ALQUILO C1-C3 O HALO; R2 ES ALQUILO C1-C5 OPCIONALMENTE SUSTITUIDO O -(CRaRb)n-Y, EN DONDE n ES 0, 1 O 2; Ra Y Rb SON CADA UNO H O METILO; Y ES HETEROCICLILO DE 4 A 6 MIEMBROS OPCIONALMENTE SUSTITUIDO, CICLOALQUILO C3-C6 OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; R3 ES H, ALCOXILO C1-C3, ENTRE OTROS; R4 ES CH O N; R5 ES H, CN O METILO; R6 ES ALCOXI C1-C3 O -O-CH2-CICLOALQUILO C3-C6. ES UN COMPUESTO PREFERIDO (R)-N-(5-CLORO-1-(3,3-DIFLUORO-1-(OXETAN-3-IL)PIPERIDIN-4-IL)-1H-PIRAZOL-4-IL)-4-ETOXI-7H-PIRROLO[2,3-d]PIRIMIDIN-2-AMINA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE LAS CINASAS LRRK2 SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, ENFERMEDAD DE ALZHEIMER
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014000139 | 2014-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20161443A1 true PE20161443A1 (es) | 2017-01-06 |
Family
ID=53756224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016001250A PE20161443A1 (es) | 2014-01-29 | 2015-01-28 | Compuestos |
Country Status (20)
Country | Link |
---|---|
US (2) | US10087186B2 (es) |
EP (1) | EP3099695B1 (es) |
JP (1) | JP6422986B2 (es) |
KR (1) | KR20160106622A (es) |
CN (1) | CN105940004B (es) |
AU (2) | AU2015210593A1 (es) |
CA (1) | CA2937431A1 (es) |
CL (1) | CL2016001895A1 (es) |
CR (1) | CR20160348A (es) |
DO (2) | DOP2016000195A (es) |
EA (1) | EA029774B1 (es) |
ES (1) | ES2802174T3 (es) |
IL (1) | IL246579B (es) |
MA (1) | MA39219B1 (es) |
MX (1) | MX367370B (es) |
PE (1) | PE20161443A1 (es) |
PH (1) | PH12016501307A1 (es) |
SG (1) | SG11201605342UA (es) |
UA (1) | UA118369C2 (es) |
WO (1) | WO2015113452A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10339791B2 (en) | 2007-06-12 | 2019-07-02 | Icontrol Networks, Inc. | Security network integrated with premise security system |
WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
EA029774B1 (ru) | 2014-01-29 | 2018-05-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
WO2015113451A1 (en) | 2014-01-29 | 2015-08-06 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
CN105153131B (zh) * | 2015-09-21 | 2017-10-17 | 马彦丽 | 一种在护理上治疗人神经胶质瘤的药物组合物 |
CN105348270B (zh) * | 2015-11-09 | 2018-01-09 | 吕显艳 | 一种防治牙体牙髓感染的药物组合物 |
WO2017087905A1 (en) * | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
EP3389663A4 (en) | 2015-12-16 | 2019-07-03 | Southern Research Institute | PYRROLOPYRIMIDINE COMPOUNDS, USE AS LACKERS OF THE LRRK2 KINASE AND METHOD FOR THE PRODUCTION THEREOF |
CN105418616B (zh) * | 2015-12-26 | 2018-01-12 | 山东大学 | 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用 |
PE20190395A1 (es) | 2016-06-16 | 2019-03-13 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos |
BR112019015278A2 (pt) * | 2017-01-25 | 2020-04-14 | Glaxosmithkline Ip Dev Ltd | compostos |
WO2018155916A2 (ko) * | 2017-02-22 | 2018-08-30 | 재단법인 대구경북첨단의료산업진흥재단 | 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
PT3604304T (pt) * | 2017-03-23 | 2022-11-30 | Korea Res Inst Bioscience & Biotechnology | Composto derivado de pirrolo-piridina, método para a sua preparação e composição farmacêutica que o contém como substância ativa para prevenção ou tratamento de doenças relacionadas com proteína quinase |
KR20200085779A (ko) | 2017-12-05 | 2020-07-15 | 주식회사 오스코텍 | Lrrk2 억제제로서의 피롤로(피라졸로)피리미딘 유도체 |
CN108715834B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种富含cd41+、cd81+微囊的血小板裂解液制备方法 |
WO2020036437A1 (ko) * | 2018-08-16 | 2020-02-20 | 재단법인 대구경북첨단의료산업진흥재단 | 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
AU2019350717A1 (en) * | 2018-09-25 | 2021-05-27 | Cardurion Pharmaceuticals, Llc | Aminopyrimidine compound |
CZ308800B6 (cs) * | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
AU2021371697B2 (en) * | 2020-10-29 | 2024-10-24 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof |
WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
US11780851B2 (en) | 2021-10-27 | 2023-10-10 | H. Lundbeck A/S | LRRK2 inhibitors |
WO2024056775A1 (en) | 2022-09-15 | 2024-03-21 | H. Lundbeck A/S | Macrocyclic leucine-rich repeat kinase 2 (lrrk2) inhibitors |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007504243A (ja) | 2003-09-03 | 2007-03-01 | ニューロジェン・コーポレーション | 5−アリール−ピラゾロ[4,3−d]ピリミジン類、ピリジン類、ピラジン類及び関連化合物 |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
US8029986B2 (en) | 2004-10-21 | 2011-10-04 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt(GmbH) | KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders |
WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
BRPI0617241A2 (pt) | 2005-10-13 | 2016-11-08 | Glaxo Group Ltd | composto ou um sal ou solvato do mesmo, composição farmacêutica, método para tratar uma doença ou condição mediada por atividade syk inadequada em um mamífero, e, uso de um composto ou um sal ou solvato farmaceuticamente aceitável do mesmo |
US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009143404A1 (en) | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
KR20120081609A (ko) * | 2009-09-29 | 2012-07-19 | 글락소 그룹 리미티드 | 신규 화합물 |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
WO2012045195A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
RS56583B1 (sr) * | 2010-11-10 | 2018-02-28 | Genentech Inc | Derivati pirazol aminopirimidina kao lrrk2 modulatori |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP2014503528A (ja) | 2010-12-14 | 2014-02-13 | エレクトロプホレトイクス リミテッド | カゼインキナーゼ1δ(CK1δ)阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用 |
CA2831634C (en) | 2011-04-21 | 2019-11-12 | Origenis Gmbh | Pyrazolo [4,3-d] pyrimidines useful as kinase inhibitors |
CN103814030A (zh) | 2011-09-22 | 2014-05-21 | 辉瑞大药厂 | 吡咯并嘧啶及嘌呤衍生物 |
BR112014012822A8 (pt) * | 2011-11-30 | 2017-07-11 | Hoffmann La Roche | Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2 |
GB201204985D0 (en) * | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
CN106279202A (zh) | 2012-05-03 | 2017-01-04 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物 |
JP6218808B2 (ja) | 2012-05-03 | 2017-10-25 | ジェネンテック, インコーポレイテッド | Lrrk2モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体 |
ES2637245T3 (es) * | 2012-06-29 | 2017-10-11 | Pfizer Inc. | Nuevas 4-(amino sustituido)-7H-pirrolo[2,3-d]pirimidinas como inhibidores de LRRK2 |
EA029774B1 (ru) | 2014-01-29 | 2018-05-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
WO2015113451A1 (en) | 2014-01-29 | 2015-08-06 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
-
2015
- 2015-01-28 EA EA201691514A patent/EA029774B1/ru not_active IP Right Cessation
- 2015-01-28 CA CA2937431A patent/CA2937431A1/en not_active Abandoned
- 2015-01-28 MA MA39219A patent/MA39219B1/fr unknown
- 2015-01-28 WO PCT/CN2015/000055 patent/WO2015113452A1/en active Application Filing
- 2015-01-28 JP JP2016549028A patent/JP6422986B2/ja not_active Expired - Fee Related
- 2015-01-28 MX MX2016009893A patent/MX367370B/es active IP Right Grant
- 2015-01-28 CN CN201580006361.XA patent/CN105940004B/zh not_active Expired - Fee Related
- 2015-01-28 EP EP15743797.1A patent/EP3099695B1/en active Active
- 2015-01-28 CR CR20160348A patent/CR20160348A/es unknown
- 2015-01-28 UA UAA201609099A patent/UA118369C2/uk unknown
- 2015-01-28 PE PE2016001250A patent/PE20161443A1/es unknown
- 2015-01-28 KR KR1020167020367A patent/KR20160106622A/ko not_active Application Discontinuation
- 2015-01-28 SG SG11201605342UA patent/SG11201605342UA/en unknown
- 2015-01-28 ES ES15743797T patent/ES2802174T3/es active Active
- 2015-01-28 US US15/114,858 patent/US10087186B2/en not_active Expired - Fee Related
- 2015-01-28 AU AU2015210593A patent/AU2015210593A1/en not_active Abandoned
-
2016
- 2016-06-30 PH PH12016501307A patent/PH12016501307A1/en unknown
- 2016-07-03 IL IL246579A patent/IL246579B/en not_active IP Right Cessation
- 2016-07-26 CL CL2016001895A patent/CL2016001895A1/es unknown
- 2016-07-29 DO DO2016000195A patent/DOP2016000195A/es unknown
-
2018
- 2018-01-12 AU AU2018200277A patent/AU2018200277B2/en not_active Ceased
- 2018-08-02 US US16/052,791 patent/US10618901B2/en not_active Expired - Fee Related
-
2019
- 2019-01-15 DO DO2019000010A patent/DOP2019000010A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20161443A1 (es) | Compuestos | |
PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
NZ732657A (en) | Picolinamides with fungicidal activity and other related compounds | |
PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
PE20141974A1 (es) | Compuestos de heterociclilo | |
PH12016501440A1 (en) | Novel heterocyclic compounds | |
PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
PE20171177A1 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
ECSP16076566A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4 | |
PE20170268A1 (es) | Compuestos de heteroarilo para la inhibicion de cinasa | |
PE20171737A1 (es) | Derivados de quinazolinona biciclicos | |
PE20160992A1 (es) | Inhibidores de quinasa relacionada con la tropomiosina (trk) | |
PE20181074A1 (es) | Compuestos heteroaromaticos como inhibidores de btk | |
PE20142164A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
ECSP18024565A (es) | Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas | |
EA201891768A1 (ru) | Кристаллическая форма a агониста tlr7, ее способ получения и использование | |
PE20180355A1 (es) | Desacetoxitubulisina h y analogos de esta | |
PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
MX2016008910A (es) | Compuestos de fenil-triazolo-piridina. | |
PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
AR100818A1 (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida |